These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 8803524

  • 1. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
    Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, Padrini R, Palatini P.
    Eur J Clin Pharmacol; 1996; 50(4):305-10. PubMed ID: 8803524
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis.
    Testa R, Campo N, Caglieris S, Risso D, Alvarez S, Arzani L, Giannini E, Lantieri PB, Celle G.
    Hepatogastroenterology; 1998 Dec; 45(19):154-9. PubMed ID: 9496506
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man.
    Bennett PN, Aarons LJ, Bending MR, Steiner JA, Rowland M.
    J Pharmacokinet Biopharm; 1982 Jun; 10(3):265-81. PubMed ID: 7175699
    [Abstract] [Full Text] [Related]

  • 9. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
    Muñoz AE, Miguez C, Rubio M, Bartellini M, Levi D, Podestá A, Niselman V, Terg R.
    Dig Dis Sci; 1999 Apr; 44(4):789-95. PubMed ID: 10219840
    [Abstract] [Full Text] [Related]

  • 10. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S, Farré M, Barral D, Torrens M, Closas N, Langohr K, Pastor A, de la Torre R.
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis.
    Mazzei T, Surrenti C, Novelli A, Biagini MR, Fallani S, Cassetta MI, Conti S, Surrenti E.
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1556-9. PubMed ID: 10390202
    [Abstract] [Full Text] [Related]

  • 12. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.
    Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara SD.
    Eur J Clin Pharmacol; 1993 Jul; 45(4):353-6. PubMed ID: 8299669
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses.
    Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, Gessa GL, Palatini P.
    Br J Clin Pharmacol; 1992 Sep; 34(3):231-5. PubMed ID: 1389947
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.
    Eur J Clin Pharmacol; 2001 Sep; 56(11):805-11. PubMed ID: 11294370
    [Abstract] [Full Text] [Related]

  • 15. The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine.
    Razak TA, McNeil JJ, Sewell RB, Drummer OH, Smallwood RA, Conway EL, Louis WJ.
    Clin Pharmacol Ther; 1990 Apr; 47(4):463-9. PubMed ID: 2328554
    [Abstract] [Full Text] [Related]

  • 16. Monoethylglycinexylidide (MEGX) as a liver function test in cirrhosis.
    Bhise SB, Dias RJ.
    Indian J Gastroenterol; 2007 Apr; 26(4):167-9. PubMed ID: 17986743
    [Abstract] [Full Text] [Related]

  • 17. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
    Sarapa N, Britto MR, Mainka MB, Parivar K.
    Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
    [Abstract] [Full Text] [Related]

  • 18. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA, O'Sullivan T, Reiss WG, Horn JR, Opheim K, Strandness DE, Carithers RL.
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [Abstract] [Full Text] [Related]

  • 19. Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis.
    Simón MA, Díez J, Prieto J.
    Gastroenterology; 1991 Nov; 101(5):1354-60. PubMed ID: 1936807
    [Abstract] [Full Text] [Related]

  • 20. Drug-drug interaction between diclofenac and gamma-hydroxybutyric acid.
    Rodriguez-Cruz V, Ren T, Morris ME.
    Biopharm Drug Dispos; 2021 Sep; 42(8):351-358. PubMed ID: 34191301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.